Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Frisone

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Praxis|March 1, 2023
Side Effects of Cancer Immunotherapies: Dermatologic and Rheumatologic ToxicitiesDaniele Frisone, Pierre O Chappuis
Current Oncology Reports|November 4, 2021
The Role and Impact of Minimal Residual Disease in NSCLCDaniele Frisone, Alex Friedlaender, Alfredo Addeo
Frontiers in Oncology|May 6, 2022
The Landscape of Immunotherapy Resistance in NSCLCDaniele Frisone, Alex Friedlaender, Alfredo Addeo, et al.
Cancer Epidemiology|July 29, 2022
Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questionsDaniele Frisone, Jose Sandoval, Alex Friedlaender, et al.
Critical Reviews in Oncology/Hematology|June 3, 2020
A BRAF new worldDaniele Frisone, Alex Friedlaender, Umberto Malapelle, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 15, 2025
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and BackAnnapaola Mariniello, Maxime Borgeaud, Marc Weiner, et al.
Cancers|July 29, 2025
Risk Factors for Arterial Thromboembolic Events in Male Germ Cell Tumors Treated with ChemotherapyDaniele Frisone, Melinda Charrier, Grégoire Berthod, et al.
Revue Medicale Suisse|July 5, 2017
[New therapeutics]Adriana Iacob Popescu, Liz Coronado, Aikaterini Efstathopoulou, et al.
Cancer Biology & Therapy|November 12, 2019
Durable response to palbociclib and letrozole in ovarian cancer with <i>CDKN2A</i> lossDaniele Frisone, Melinda Charrier, Sophie Clement, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Praxis|March 1, 2023
Side Effects of Cancer Immunotherapies: Dermatologic and Rheumatologic ToxicitiesDaniele Frisone, Pierre O Chappuis
Current Oncology Reports|November 4, 2021
The Role and Impact of Minimal Residual Disease in NSCLCDaniele Frisone, Alex Friedlaender, Alfredo Addeo
Frontiers in Oncology|May 6, 2022
The Landscape of Immunotherapy Resistance in NSCLCDaniele Frisone, Alex Friedlaender, Alfredo Addeo, et al.
Cancer Epidemiology|July 29, 2022
Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questionsDaniele Frisone, Jose Sandoval, Alex Friedlaender, et al.
Critical Reviews in Oncology/Hematology|June 3, 2020
A BRAF new worldDaniele Frisone, Alex Friedlaender, Umberto Malapelle, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 15, 2025
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and BackAnnapaola Mariniello, Maxime Borgeaud, Marc Weiner, et al.
Cancers|July 29, 2025
Risk Factors for Arterial Thromboembolic Events in Male Germ Cell Tumors Treated with ChemotherapyDaniele Frisone, Melinda Charrier, Grégoire Berthod, et al.
Revue Medicale Suisse|July 5, 2017
[New therapeutics]Adriana Iacob Popescu, Liz Coronado, Aikaterini Efstathopoulou, et al.
Cancer Biology & Therapy|November 12, 2019
Durable response to palbociclib and letrozole in ovarian cancer with <i>CDKN2A</i> lossDaniele Frisone, Melinda Charrier, Sophie Clement, et al.
Pageof 1